NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
68 trialsNCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
NCT06508463 2026-03-16
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06708949 2026-03-13
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04697576 2026-03-10
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05048212 2026-03-02
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07128680 2026-02-27
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07188896 2026-02-23
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07422779 2026-02-20
MAK
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT05715229 2026-02-18
G360-IIT
Hackensack Meridian Health
Phase 2 Recruiting
NCT06353646 2026-02-13
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT07230613 2026-02-11
NEOREM-NEO-1
UNICANCER
Phase 2 Recruiting
NCT07394062 2026-02-06
ALCG-01
Gazi University
Recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT04562129 2026-01-29
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06365619 2026-01-29
NeoRelapse
University of Utah
Phase 2 Recruiting
NCT06324240 2026-01-26
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Phase 1 Recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT06295159 2026-01-08
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06968988 2026-01-08
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 1 Recruiting
NCT05779423 2026-01-06
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT04933903 2025-12-30
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Brown University
Phase 2 Recruiting
NCT06889493 2025-12-17
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04248569 2025-12-03
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT07155317 2025-11-12
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
Phase 2 Recruiting
NCT03546686 2025-10-27
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT05407441 2025-10-03
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06866262 2025-09-09
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT06712927 2025-09-08
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT06364917 2025-09-03
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT07134842 2025-08-21
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT03646617 2025-08-13
RadVax
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05732389 2025-08-07
RESET-R
Odense University Hospital
Phase 2 Recruiting
NCT03690986 2025-07-23
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Emory University
Phase 1 Recruiting
NCT05361720 2025-07-23
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT06377111 2025-07-14
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Phase 1 Recruiting
NCT04003649 2025-07-10
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Phase 1 Recruiting
NCT04464759 2025-07-08
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT05310643 2025-07-01
NIPIRESCUE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting